Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Outcomes of COVID-19 Infection in Patients Receiving Ruxolitinib and Hypomethylating Agent Therapy

Daniel I. Nathan, MD, Douglas Tremblay, MD, Santiago Thibaud, MD, John Mascarenhas, MD, Janice L. Gabrilove, MD

Blood (2020) 136 (Supplement 1): 30.

https://doi.org/10.1182/blood-2020-137005

Published: 2020

Journal Articles

Prognostic Significance of Hospitalization Status at Second Cycle of Hypomethylating Agent Induction Therapy in Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Douglas Tremblay, MD, Rafael Madero-Marroquin, MD, Guido Lancman, MD, Alexander Coltoff, MD, Jonathan Feld, MD, Jessica Caro, MD, Nicole Zubizarreta, MPH, Marina Kremyanskaya, Alla Keyzner, MD, Michal Bar-Natan, MD, Shyamala C. Navada, MD, Lewis R. Silverman, Janice L. Gabrilove, MD, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 5102.

https://doi.org/10.1182/blood-2019-123288

Published: 2019

Journal Articles

Azacitidine With Or Without Entinostat For The Treatment Of Therapy-Related Myeloid Neoplasm: Further Results Of The E1905 North American Leukemia Intergroup Study

Thomas Prebet, MD, PhD, Zhuoxin Sun, PhD, Rhett Ketterling, MD, Peter L. Greenberg, MD, Amer M. Zeidan, MD, Mark R. Litzow, MD, Janice L. Gabrilove, MD, Harry Paul Erba, MD, PhD, Elisabeth Paietta, PhD, Magdalena Czader, MD, PhD, Steven D Gore, Martin S Tallman, MD

Blood (2013) 122 (21): 2777.

https://doi.org/10.1182/blood.V122.21.2777.2777

Published: 2013

Journal Articles

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy

Hagop M. Kantarjian, Francis J. Giles, Peter L. Greenberg, Ron L. Paquette, Eunice S. Wang, Janice L. Gabrilove, Guillermo Garcia-Manero, Kuolung Hu, Janet L. Franklin, Dietmar P. Berger

Blood (2010) 116 (17): 3163–3170.

https://doi.org/10.1182/blood-2010-03-274753

Published: 2010

Journal Articles

Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM).

Ruben Niesvizky, MD, Scott Ely, MD, MPH, Maurizio DiLiberto, PhD, Hearn J. Cho, MD, PhD, Udi Y. Gelbshtein, David S. Jayabalan, Sangeeta Aggarwal, MD, Janice L. Gabrilove, MD, Roger N. Pearse, MD, PhD, Karen Pekle, RN, ANPC, Faiza Zafar, RPAC, Zoe Goldberg, MD, John P. Leonard, MD, John J. Wright, MD, Selina Chen-Kiang, PhD, Morton Coleman, MD

Blood (2005) 106 (11): 2574.

https://doi.org/10.1182/blood.V106.11.2574.2574

Published: 2005

Journal Articles

A Phase I-II Pilot Study of Divalproex Sodium Alone and in Combination with All-Trans-Retinoic Acid (ATRA) in Relapsed or Refractory Acute Myeloid Leukemia.

Janice L. Gabrilove, MD, Melanie-Jane McConnell, MD, Windy Berkofsky-Fessler, MD, Andres L. Sirulnik, MD, PhD, Sanjay Sharma, MD, Lewis R. Silverman, MD, Luis Isola, MD, John Mandeli, PhD, Jonathan Licht, MD

Blood (2005) 106 (11): 2799.

https://doi.org/10.1182/blood.V106.11.2799.2799

Published: 2005

Journal Articles

Thalidomide Is Active Alone and in Combination with Fludarabine in Fludarabine-Relapsed and Refractory Chronic Lymphocytic Leukemia.

Richard R. Furman, MD, Steven L. Allen, MD, John P. Leonard, MD, Morton Coleman, MD, Jessica M. Markis, Janice L. Gabrilove, MD

Blood (2004) 104 (11): 4835.

https://doi.org/10.1182/blood.V104.11.4835.4835

Published: 2004

Journal Articles

Phase I Study of Rituximab-Cyclophosphamide (R-CY) Stem Cell Mobilization and Rituximab-BEAM HDC with ASCT in Patients with Relapsed, Refractory or High Risk Intermediate Grade Non-Hodgkin’s Lymphoma.

Eileen Scigliano, M.D., Celia L. Grosskreutz, M.D., Steven M. Fruchtman, M.D., Janice L. Gabrilove, M.D., John P. Mandeli, Ph.D., Luis M. Isola, M.D.

Blood (2004) 104 (11): 5225.

https://doi.org/10.1182/blood.V104.11.5225.5225

Published: 2004

Journal Articles

Sequential Phase II Studies of Flavopiridol by 72-Hour Continuous Infusion and 1-Hour Intravenous Bolus for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia: Results from CALGB Study 19805.

John C. Byrd, MD, Bercedis L. Peterson, PhD, Janice L. Gabrilove, MD, Olatoyosi M. Odenike, MD, Michael R. Grever, MD, Kanti R. Rai, MD, James W. Vardiman, MD, Richard A. Larson, MD, Cancer and Leukemia Group B

Blood (2004) 104 (11): 3485.

https://doi.org/10.1182/blood.V104.11.3485.3485

Published: 2004

Journal Articles

Arsenic Trioxide and Melarsoprol Induce Programmed Cell Death in Myeloid Leukemia Cell Lines and Function in a PML and PML-RAR Independent Manner

Zhu-Gang Wang, Roberta Rivi, Laurent Delva, Andrea König, David A. Scheinberg, Carlo Gambacorti-Passerini, Janice L. Gabrilove, Raymond P. Warrell, Jr, Pier Paolo Pandolfi

Blood (1998) 92 (5): 1497–1504.

https://doi.org/10.1182/blood.V92.5.1497

Published: 1998

Journal Articles

The Novel Cyclin-Dependent Kinase Inhibitor Flavopiridol Downregulates Bcl-2 and Induces Growth Arrest and Apoptosis in Chronic B-Cell Leukemia Lines

Andrea König, Gary K. Schwartz, Ramzi M. Mohammad, Ayad Al-Katib, Janice L. Gabrilove

Blood (1997) 90 (11): 4307–4312.

https://doi.org/10.1182/blood.V90.11.4307

Published: 1997

Journal Articles

Comparative Activity of Melarsoprol and Arsenic Trioxide in Chronic B-Cell Leukemia Lines

Andrea König, Laura Wrazel, Raymond P. Warrell, Jr, Roberta Rivi, Pier Paolo Pandolfi, Ann Jakubowski, Janice L. Gabrilove

Blood (1997) 90 (2): 562–570.

https://doi.org/10.1182/blood.V90.2.562

Published: 1997

NARROW

Outcomes of COVID-19 Infection in Patients Receiving Ruxolitinib and Hypomethylating Agent Therapy

Prognostic Significance of Hospitalization Status at Second Cycle of Hypomethylating Agent Induction Therapy in Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Azacitidine With Or Without Entinostat For The Treatment Of Therapy-Related Myeloid Neoplasm: Further Results Of The E1905 North American Leukemia Intergroup Study

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy

Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM).

A Phase I-II Pilot Study of Divalproex Sodium Alone and in Combination with All-Trans-Retinoic Acid (ATRA) in Relapsed or Refractory Acute Myeloid Leukemia.

Thalidomide Is Active Alone and in Combination with Fludarabine in Fludarabine-Relapsed and Refractory Chronic Lymphocytic Leukemia.

Phase I Study of Rituximab-Cyclophosphamide (R-CY) Stem Cell Mobilization and Rituximab-BEAM HDC with ASCT in Patients with Relapsed, Refractory or High Risk Intermediate Grade Non-Hodgkin’s Lymphoma.

Sequential Phase II Studies of Flavopiridol by 72-Hour Continuous Infusion and 1-Hour Intravenous Bolus for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia: Results from CALGB Study 19805.

Arsenic Trioxide and Melarsoprol Induce Programmed Cell Death in Myeloid Leukemia Cell Lines and Function in a PML and PML-RAR Independent Manner

The Novel Cyclin-Dependent Kinase Inhibitor Flavopiridol Downregulates Bcl-2 and Induces Growth Arrest and Apoptosis in Chronic B-Cell Leukemia Lines

Comparative Activity of Melarsoprol and Arsenic Trioxide in Chronic B-Cell Leukemia Lines

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only